COMMD10: A Potential Drug Target for Neurological Disorders (G51397)

Target Name: COMMD10

NCBI ID: G51397

COMMD10

COMMD10: A Potential Drug Target for Neurological Disorders

COMMD10 (COMDA\\_HUMAN), also known as GFAP, is a protein that is expressed in various tissues of the human body, including the brain, nervous system, and muscles. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling.

COMMD10 is a 21-kDa protein that is expressed in the brain, where it is involved in the development and maintenance of neural circuits. It is a key regulator of the neurotransmitter release from neurotransmitter-producing neurons, and it is involved in the regulation of neurotransmitter signaling.

COMMD10 is highly expressed in the brain and is primarily localized to the dendrites of neurons, where it is involved in the regulation of neurotransmitter release. It is also expressed in other tissues, including the nervous system and muscles, where it is involved in the regulation of neural circuits.

COMMD10 is a protein that is currently being targeted by researchers as a potential drug target for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the reasons for the potential targeting of COMMD10 is its involvement in the regulation of neurotransmitter signaling, which is a crucial aspect of brain function. Neurotransmitters are the chemical messengers that are used by neurons to communicate with each other, and the regulation of neurotransmitter signaling is essential for the development and maintenance of neural circuits.

COMMD10 is involved in the regulation of neurotransmitter release from neurotransmitter-producing neurons, which is critical for the proper functioning of neural circuits. It does this by interacting with a variety of intracellular signaling pathways, including the regulation of protein kinase (PKA), which is a critical regulator of protein synthesis and degradation.

COMMD10 is also involved in the regulation of neurotransmitter uptake and release, which is another critical aspect of neurotransmission. It does this by interacting with the neurotransmitter transporter, which is responsible for transporting neurotransmitters across the membrane of the neuron.

In addition to its role in the regulation of neurotransmitter signaling, COMMD10 is also involved in the regulation of neurotransmitter release from endogenous sources, such as neuropeptides. This is important for the proper functioning of neural circuits, as neuropeptides are often used as signaling molecules in the brain.

COMMD10 is a protein that is expressed in various tissues of the human body, and it is involved in the regulation of neural circuits. Its involvement in the regulation of neurotransmitter signaling and neurotransmission makes it a potential drug target for the treatment of various neurological and psychiatric disorders.

COMMD10 is a protein that is being targeted by researchers as a potential drug target for the treatment of Alzheimer's disease, Parkinson's disease, and depression. Studies have shown that COMMD10 is highly expressed in the brains of individuals with these disorders, and that it is involved in the regulation of neurotransmission.

In addition to its potential clinical applications, COMMD10 is also a valuable research tool for the study of neurotransmission. Its expression is highly regulated in the brain, and researchers can use it as a protein of interest to study the mechanisms of neurotransmission.

Overall, COMMD10 is a protein that is involved in the regulation of neural circuits and is a potential drug target for the treatment of various neurological and psychiatric disorders. Further research is needed to fully understand its role in neurotransmission and its potential as a therapeutic target.

Protein Name: COMM Domain Containing 10

Functions: May modulate activity of cullin-RING E3 ubiquitin ligase (CRL) complexes (PubMed:21778237). May down-regulate activation of NF-kappa-B (PubMed:15799966)

The "COMMD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COMMD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets